Evidence from pre/post, quasi-experimental, and some randomized interventions supports the benefits of FIM for food security, nutrition security, diet quality, blood glucose control, hypertension, disease self-management, self-perceived physical and mental health, and health care utilization [222]
What the research actually shows about depression, anxiety, and quality of life
A2A adenosine receptor overexpression and functionality, as well as TNF- levels, correlate with motor symptoms in Parkinsons disease
The question behind the question is usually: "How much longer will I be able to get compounded semaglutide at this price?" The pattern we see: patients conflate three separate timelines: Patent expiration (2031-2033 for the formulations that matter) FDA shortage list removal (expected late 2026 to Q1 2027) Generic market entry (2027 for oral, 2031-2032 for injectable, assuming no patent challenges) The timeline that affects current compounded access is number 2, not number 1
The correlation between functional connectivity and metabolism is sometimes preserved as the state of the brain changes, e.g
Add milk the night before, grab it in the morning